CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
EQS Group
Issuer: CureVac / Key word(s): Annual Results
24.04.2024 / 13:06 CET/CEST
The issuer is solely responsible for the..
SARS-CoV-2 Omicron variant
News and Video Search Results
News coverage
-
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Accesswire
-
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
GlobeNewswire
-
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
-
Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
Accesswire
- More about:
Eui-Cheol Shin
0 shares
2 views
You might like
SARS-CoV-2 Omicron variant media coverage
Evolution Of Human Immune System In Post-Omicron Era
Eurasia Review
It has been 4 years since the start of the COVID-19 pandemic. SARS-CoV-2 has yet to be eradicated and new variants are continuously..
-
SARS-CoV-2 BA.2.86 is less resistant to vaccine, but may be a problem in the lung
Science Daily
-
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Accesswire
-
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
GlobeNewswire
-
Zentek Launches Triera Biosciences Ltd.
Accesswire
Advertisement
More coverage
Zentek Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant
Accesswire
*GUELPH, ON / ACCESSWIRE / November 29, 2023 / Zentek Ltd.* ("*Zentek*" or the "*Company*") (NASDAQ:ZTEK)(TSX-V:ZEN), an..